HSV529 Vaccine in HSV-2 Seropositive Adults

Phase 1 Completed 10 enrolled Fred Hutchinson Cancer Center Sanofi Pasteur, a Sanofi Company · collab University of Washington · collab

NaSingle-groupOpen-labelTreatment

Summary

The purpose of the study is to determine the safety of HSV529 vaccine in healthy volunteers with HSV infection and to determine if administration of the HSV529 vaccine increases the immune response in genital skin.

Timeline

Start: 2015-11
Primary completion: 2018-12-01
Completion: 2018-12-01

Publications

Ford ES, Li AZ, Laing KJ, Dong L, Diem K, Jing L, Mayer-Blackwell K, Basu K, Ott M, Tartaglia J, Gurunathan S, Reid JL, Ecsedi M, Chapuis AG, Huang ML, Magaret AS, Johnston C, Zhu J, Koelle DM, Corey L. Expansion of the HSV-2-specific T cell repertoire in skin after immunotherapeutic HSV-2 vaccine. JCI Insight. 2024 Jun 18;9(14):e179010. doi: 10.1172/jci.insight.179010.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	HSV529	Vaccine	—	—
Background	Valacyclovir	Unknown	500 mg	Oral

HSV529 Vaccine in HSV-2 Seropositive Adults

Summary

Timeline

Publications

Drugs

Indications